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Abstract
Background: The present study was designed to investigate the efficacy of a new formulation of alone, purified
cannabidiol (CBD) (>98 %), the main non-psychotropic cannabinoid of Cannabis sativa, as a topical treatment in an
experimental model of autoimmune encephalomyelitis (EAE), the most commonly used model for multiple sclerosis
(MS). Particularly, we evaluated whether administration of a topical 1 % CBD-cream, given at the time of symptomatic
disease onset, could affect the EAE progression and if this treatment could also recover paralysis of hind limbs, qualifying
topical-CBD for the symptomatic treatment of MS.
Methods: In order to have a preparation of 1 % of CBD-cream, pure CBD have been solubilized in propylene
glycoland basic dense cream O/A. EAE was induced by immunization with myelin oligodendroglial glycoprotein
peptide (MOG35–55) in C57BL/6 mice. After EAE onset, mice were allocated into several experimental groups
(Naïve, EAE, EAE-1 % CBD-cream, EAE-vehicle cream, CTRL-1 % CBD-cream, CTRL-vehicle cream). Mice were observed daily
for signs of EAE and weight loss. At the sacrifice of the animals, which occurred at the 28th day from EAE-induction, spinal
cord and spleen tissues were collected in order to perform histological evaluation, immunohistochemistry and western
blotting analysis.
Results: Achieved results surprisingly show that daily treatment with topical 1 % CBD-cream may exert neuroprotective
effects against EAE, diminishing clinical disease score (mean of 5.0 in EAE mice vs 1.5 in EAE + CBD-cream), by recovering
of paralysis of hind limbs and by ameliorating histological score typical of disease (lymphocytic infiltration and
demyelination) in spinal cord tissues. Also, 1 % CBD-cream is able to counteract the EAE-induced damage reducing
release of CD4 and CD8α T cells (spleen tissue localization was quantified about 10,69 % and 35,96 % of positive staining
respectively in EAE mice) and expression of the main pro-inflammatory cytokines as well as several other direct or indirect
markers of inflammation (p-selectin, IL-10, GFAP, Foxp3, TGF-β, IFN-γ), oxidative injury (Nitrotyrosine, iNOS, PARP) and
apoptosis (Cleaved caspase 3).
Conclusion: All these data suggest an interesting new profile of CBD that could lead to its introduction in the clinical
management of MS and its associated symptoms at least in association with current conventional therapy.
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Background
Cannabidiol (CBD) is the major non psychotropic con-
stituent naturally present in Cannabis sativa L. plant
isolated across the 1930s and 1940s, but chemically
identified only in the 1960s by Mechoulam et al. [1]. As
well documented from Cannabis sativa L. it is also pos-
sible to extract over 100 different cannabinoids com-
pounds considered as its most important bioactive
constituents and mainly known for their psychoactive ef-
fects [2]. Among these the main studied is the Δ9-tetra-
hydrocannabinol (Δ9-THC). This class of compounds
have their effect mainly by interacting with specific re-
ceptors: the cannabinoid receptor type 1 (CB1), found
on neurons and glial cells in various parts of the brain,
and the cannabinoid receptor type 2 (CB2), found
mainly in the body’s immune system [3, 4]. On the con-
trary, CBD has a very low affinity for these receptors
(100 fold less than Δ9-THC) and when it binds it pro-
duces little to no effect [5].
CBD is able to exert multiple pharmacological actions
via no-CB1 and no-CB2 receptors involving intracellular
pathways that play a key role in neuronal physiology [6, 7].
In particular, many actions of CBD seem to be mediated by
binding transient receptor potential vanilloid type 1
(TRPV1) [8], G protein-coupled receptor 55 (GPR55) [6, 9]
and 5-hydroxytryptamine receptor subtype 1A (5-HT1A)
[10]. These additional and novel cannabinoid receptors
(no-CB1 and no-CB2) have been identified in CB1 and
CB2- knockout mice and are expressed in both central and
peripheral nervous system [11, 12].
Moreover, CBD has proved to have several anti-
inflammatory activities and regulates cell cycle and im-
mune cells functions [13]. CBD is able to suppress the
production of a wide range of pro-inflammatory cyto-
kines, such as tumor necrosis factor (TNF)-α and
interleukin-1 beta (IL-1β), chemokines, growth factors,
as well as inhibition of immune cell proliferation, activa-
tion, maturation, migration and antigen presentation
[14, 15]. CBD shows also a potent action in inhibiting
oxidative and nitrosative stress, modulating the expres-
sion of inducible nitric oxide synthase (iNOS) and nitro-
tyrosine as well as reducing production of reactive
oxygen species (ROS) [16].
Just about all these properties showed by CBD, have
prompted researchers to test its effects in a number of
conditions involving both inflammation and oxidative
stress, like neurodegenerative diseases, demonstrating in
cell cultures as well as in animal models evident neuro-
protective effects [16, 17].
Among this kind of disorders, multiple sclerosis
(MS) is one of those obviously induced and driven by
an unusual response of the immune system cells (T
and B-lymphocytes) against myelin sheats of neurons
[18]. During MS myelin autoreactive peripheral T cells
migrate into the CNS and initiate cytotoxic, degenerative
processes that include demyelination, oligodendrocyte cell
death and axonal degeneration [15]. These effects lead to
main clinical symptoms and neurological deficits [19].
According to the National MS Society, spasticity it is a
common symptom in people suffering from MS. When
MS damages the nerves that control muscles, it can re-
sult in spasticity that impairs movement and causes pain
and stiffness. It usually occurs in the legs and can draw
them up toward the body with painful cramping or
cause spasms in the lower back, until losing the sensitiv-
ity of the limbs.
To date, current treatments for MS only offer pallia-
tive relief without providing a cure, and many are also
associated with adverse effects that limit their long-term
utility [20].
To overcome these limits, the interest of researchers
was focused on finding alternative cure that could be
less invasive and that may use for the treatment of MS
and its correlated symptoms.
Numerous studies have been performed to evaluate the
role of cannabinoids on treatment of EAE-associated spasti-
city as well as on modulation of the neurodegenerative
process [21–25]. In this context, CBD has been proven to
decrease peripheral inflammation and neuroinflammation
in EAE mice when systemically given at the time of
symptomatic disease [25]. In addition CBD is able to
affect disease progression and ameliorated clinical
symptoms. Moreover, CBD-Glatiramer Acetate (GA) com-
bination administered in nasal delivery system (NDS) re-
sulted in a statistically significant decrease of clinical scores
and inflammatory cytokine expression in EAE mice [26].
Moreover, according to the two most relevant double-
blind, randomized, placebo-controlled trials, benefits
from use of cannabinoids seen in animal studies have
also been shown in the treatment of MS patients suffer-
ing spasticity, with a significant associated disability and
quality of life impairment [27, 28].
To date, the only commercially available preparation
containing cannabinoids is Sativex® (GW Pharma, Ltd,
Salisbury, Wiltshire, UK), an oral spray containing a
mixture of two extracts in approximately a 1:1 ratio
standardized to contain 2.7 mg of Δ9-THC and 2.5 mg
of CBD/ 0.1 mL in an aromatized water-ethanol solu-
tion. Sativex® is used to alleviate spasticity in adult MS
patients who do not show appropriate response to other
drugs during an initial trial period of therapy [29].
Compared to other routes of administration, its advan-
tage is a faster plateau of plasma concentration. Also, it
has been established that coadministration of CBD and
Δ9-THC can reduce unwanted effects of Δ9-THC [30].
The aim of this work was to study for the first time
the effects of a topical administration of alone, purified
CBD, as a new treatment strategy for MS. In specific, we
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evaluated whether treatment with a topical 1 % CBD-
cream given at the time of symptomatic disease onset,
could ameliorate the progression of the disease, counter-
acting the overall cascade of events occurring after EAE
induction in mice. In addition, we investigated whether
1 % CBD-cream treatment could enhance responsiveness
to a mechanical stimulus and recover paralysis of the
hind limbs, qualifying topical-CBD for the symptomatic
treatment of MS.
By examining this profile of CBD, we strongly hope to
provide new evidences about the efficacy of the new top-
ical treatment and to contribute into delineating a
clearer profile of the compound so that its use could be
an alternative to oral and parenteral administration of
drugs for treatment of autoimmune and neurodegenera-
tive diseases, like MS.
Methods
Plant material
Cannabis sativa L, derived from greenhouse cultivation
at CRA-CIN, Rovigo (Italy), where a voucher specimen
is kept, was collected in November 2013. The isolation
and manipulation of cannabinoids was done in accord-
ance with their legal status (Authorization SP/106 23/
05/2013 of the Ministry of Health, Rome, Italy).
Extraction and Isolation of CBD
Pure CBD (>98 %) was isolated from an Italian variety of
industrial hemp (Carmagnola) according to the method
of the cannabinoid purification reported in Taglialatela-
Scafati O. et al. [31] with some modifications in order to
avoid any trace of Δ9-THC that could interfere in the
trial or causes legal limitation.
Dried flowerheads of Cannabis sativa (500 g) were
heated at 120 °C in a ventilated oven for 2.5 h to decarb-
oxylate pre-cannabinoids. After cooling to room
temperature, the plant material was extracted with acet-
one (210 L). Removal of the solvent left a gummy resi-
due that was partitioned between 1:1 aqueous methanol
(1 L) and petroleum ether (1 L). The defatted polar
phase was concentrated and extracted with CH2Cl2. The
organic phase was dried (Na2SO4) and evaporated to af-
ford a black gum (10 g), which was purified by flash
chromatography on RP-18 silica gel (Biotage equipment,
250 mL column, linear gradient, from methanol water
55:45 to 90:10). Overall, five fractions were collected.
The more polar one was further fractionated by gravity
column chromatography on silica gel, with use of acid-
ified (0.5 % HOAc) petroleum ether/EtOAc mixtures.
After four chromatographic steps, crude CBD (10 mg)
was obtained from a fraction directly eluted. The crude
fraction was further purified by HPLC (eluentn-hexane/
EtOAc 7:3) to provide pure CBD (6, 7.0 mg, 14 ppm
based on dried plant material).
Finally the purity of CBD of 98 % was estimated by
HPLC analysis according to the method of American
Herbal Pharmacopoeia as reported in Swift et al. [32].
Cream preparation
Pure CBD have been solubilized in propylene glycoland
basic dense cream O/A to have a concentration of 1 %
of CBD. Each application for both hind limbs regards a
surface of about 1 cm2.
Animals
Male C57BL/6 mice (Harlan Milan, Italy) 12 weeks of
age and weighing 20–25 g were housed in individually
ventilated cages with food and water ad libitum. The
room was maintained at a constant temperature and hu-
midity on a 12 h/12 h light/dark cycle.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the guide for the care and use of
laboratory animals of the National Institutes of Health.
The protocol was approved by the Ministry of Health
“General Direction of animal health and veterinary drug”
(Authorization 150/2014-B 28/03/2014). In particular,
animal care was in compliance with Italian regulations
on protection of animals used for experimental and
other scientific purposes (D.M. 116/92) as well as with
the EEC regulations (O.J. of E.C.L 358/1 12/18/1986).
Also, it was minimized number of animals used for this
experiment and their suffering.
Induction of Experimental Autoimmune
Encephalomyelitis (EAE)
After anesthesia, induced with an anesthetic cocktail com-
posed of tiletamine plus xylazine (10 ml/kg, ip), EAE was
actively induced using Myelin Oligodendrocyte Glyco-
protein peptide (MOG)35–55 (MEVGWYRSPFSRVVH-
LYRNGK; % peak area by HPLC ≥ 95, AnaSpec, EGT
Corporate Headquarters, Fremont, CA, USA), according
to Paschalidis et al. [33]. Mice were immunized subcuta-
neously with 300 μl/flank of the emulsion consisting of
300 μg of (MOG)35–55 in phosphate-buffered saline (PBS)
mixed with an equal volume of Complete Freund’s Adju-
vant (CFA) containing 300 μg heat-killed M. Tubercolosis
H37Ra (Difco Laboratories Sparks, MD,USA). Immedi-
ately after (MOG)35–55 injection, the animals received an
ip injection of 100 μl of B. Pertussis toxin (Sigma-Aldrich,
Milan, Italy) (500 ng/100 μl, i.p), repeated 48 h later. The
disease follows a course of progressive degeneration, with
visible signs of pathology consisting of flaccidity of the tail
and loss of motion of the hind legs.
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Experimental design
Mice were randomly allocated into the following groups
(N = 40 total animals):
1. Naive group (N = 5): mice did not receive
(MOG)35–55 or other treatment;
2. EAE group (N = 10): mice subjected to EAE that did
not receive pharmacological treatment;
3. EAE + 1% CBD-cream treatment group (N = 10):
EAE mice were subjected to one topical treatment of
lower limbs with the 1 % CBD-cream every 24 h. In
specific, before the beginning of treatment all animals
were subjected to shaving of both hind limbs in outer
thigh (area of 1 cm2) to facilitate the absorption of
cream. Indeed, at each treatment cream was spread in
this area until fully absorbed, also to prevent that
animals could eat or lick cream. Only after the animals
were placed in their cages. The treatment was started
after the onset of disease signs and then daily
protracted until the sacrifice;
4. EAE + vehicle cream (no plus CBD) group (N = 5):
mice subjected to the same condition of the above
group, but treated every 24 h with one topical
application of the basic cream without CBD until
the sacrifice;
5. CTRL group + 1 % CBD-cream (N = 5): mice
subjected to shaving of both hind limbs in outer
thigh (area of 1 cm2) and every 24 h subjected to
one topical application with the 1 % CBD-cream that
was spread until fully absorbed;
6. CTRL group + vehicle cream (no plus CBD) (N = 5):
mice subjected to the same condition of the above
group, but every 24 h treated with one topical
application of the basic cream without CBD.
Of note, the last two groups were provided to verify if
any beneficial effect was ascribed to the method of ad-
ministration of the cream, such as spreading or whether
treatment with 1 % CBD-cream or vehicle cream) could
cause some allergic reaction in mice at cutaneous either
at systemic level.
At the end of the experiment, which occurred at the
28th day from EAE-induction, animals were euthanized
with ip of Tanax (5 ml/kg body weight). Also, spinal
cord tissues and spleen were sampled and processed in
order to evaluate parameters of disease.
Schematically, a plan of the experiment is shown in
Fig. 1a.
Clinical disease score and body weight evaluation
14 days after EAE induction, mice show the first signs of
MS disease, characterized by loss of tail tonus, hind limb
paralysis and body weight loss. Clinical score was evalu-
ated according to a standardized scoring system [34] as
follows: 0 = no signs; 1 = partial flaccid tail; 2 = complete
flaccid tail; 3 = hind limb hypotonia; 4 = partial hind limb
paralysis; 5 = complete hind limb paralysis; 6 =moribund
or dead animal. Animals with a score ≥ 5 were sacrificed
to avoid animal suffering.
The first measurement of clinical disease score and
body weight were taken on the day of EAE- induction
(day zero), and all the subsequent measurements were
recorded every 48 h until sacrifice. Also, the daily vari-
ation of these two parameters of disease has been
expressed compared to day of EAE induction (day zero).
The value day has been expressed as mean ± SEM of all
animals for each experimental group.
Needle test
The test was aimed to assess mice’s responsiveness to a
mechanical stimulus. It starts with the filament of
0.02 g, applying force to the left paw three times for a
total period of 30 s (about 2 s to the stimulus) and to
evaluate the response of the mouse after each applica-
tion. The same treatment is repeated on the right paw.
Response to two on three stimuli is regarded as a posi-
tive reaction. Specifically, a positive response is a paw
withdrawal from the stimulus. The maximum score for
both paws has a value of 6. In specific, 7 tests were per-
formed every 48 h in two weeks from the first adminis-
tration of 1 % CBD-cream. Animals were subjected to
these measurements every 48 h in order to avoid add-
itional stress that could affect the results. The values are
expressed as mean ± SEM of each group.
Blood sampling
At the time of sacrifice, following anesthesia blood sam-
ples were collected via cardiac injection in EDTA K2/gel
tubes (BD Vacutainer® BD Diagnostic, Milan Italy) and
centrifuged following at least 30 min from the collection
at 10,000 g speed for 5 min. The achieved plasma was
collected, aliquoted and stored at −20 °C to be used for
detection of CBD.
Pharmacokinetic analysis
Pharmacokinetc analysis of CBD plasma concentration
was performed by liquid chromatography followed by
mass spectrometry detection according to a reported
method [38] with some modifications.
May Grunwald Giemsa staining
At 28 days following EAE-induction, spinal cords were
fully sampled from cervical to lumbar area and were
fixed in 10 % (w/v) PBS-buffered formaldehyde. Spinal
cord samples were first paraffin-embedded and cut into
7 μm-thick sections and then were deparaffinized with
xylene, rehydrated, stained with May Grunwald Giemsa
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and studied using light microscopy (Leica ICC50HD
microscope).
May Grunwald Giemsa staining was performed accord-
ing to the manufacturer’s protocol (Bio-Optica, Milan,
Italy) for the differentiation of cells present in lymphohe-
mopoietic tissues. The staining solutions contain methy-
lene blue (a basic dye), related azures (also basic dyes) and
eosin (an acid dye). The first involves a blue/purple stain-
ing, the second involves a pink/red staining. The staining
provides the nuclei of white blood cells and the granules
of basophil granulocytes in blue, while red blood cells and
eosinophil granules in red.
Luxol Fast Blue (LFB)
To show myelin and phospholipids in histological sec-
tions, LFB staining was performed according to the
manufacturer’s protocol (Bio-Optica, Milan, Italy). LFB
affinity for central nervous system is usually ascribed to
the bonds it forms with phospholipidic structures such
as lecithin and sphingomyelin. The staining provides:
myelin in turquoise blue, neurons and glial nuclei in
pink/violet and Nissl substance in pale pink.
Immunohistochemical evaluation
After deparaffinization with xylene, sections of spinal
cord and spleen samples were hydrated. Detection of
FOXP3, CD4, CD8α, GFAP, p-selectin, IL-1β, iNOS,
nitrotyrosine and PARP-1 was carried out after boil-
ing in citrate buffer 0.01 M pH 6 for 4 min. En-
dogenous peroxidase was quenched with 0.3 % (v/v)
hydrogen peroxide in 60 % (v/v) methanol for
30 min. Nonspecific adsorption was minimized by in-
cubating the section in 2 % (v/v) normal goat serum
in PBS for 20 min.
Sections were incubated overnight with:
 anti-FOXP3 monoclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc);
Fig. 1 Panel a shows timeline of experimental design. EAE was induced on the 0th day. The disease onset occurred on the 14th day
simultaneously daily treatment with CBD-cream was started and protracted until the day of sacrifice, which occurred at the 28th day. Mice were
immunized with MOG35–55 and monitored for clinical disease score of EAE (b) and body weight variations (x). Data have been expressed as mean
± SEM of all measurements of each experimental group. A p value < 0.05 was considered statistically significant. *p < 0.03 vs NAIVE, **p < 0.0011 vs
NAÏVE (b). ****p < 0.0001 vs NAIVE, °°p < 0.0016, °°°°p < 0.0001 vs CBD-cream (c). Panel d displays score of sensibility measured by needle test
****p < 0.0001 vs NAÏVE, °°p < 0.0011, °°°p < 0.004, °°°°p < 0.0001 vs CBD-cream
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 anti-CD4 polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc);
 anti-CD8α polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc);
 anti-GFAP monoclonal antibody (1:50 in PBS v/v;
Cell Signaling Technology);
 anti-p-selectin polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc);
 anti-IL-1β polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc);
 anti iNOS polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc);
 anti-nitrotyrosine polyclonal antibody (1:100 in PBS
v/v; Millipore);
 anti-PARP-1 polyclonal antibody (1:100 in PBS v/v;
Santa Cruz Biotechnology, Inc).
Endogenous biotin or avidin binding sites were
blocked by sequential incubation for 15 min with bio-
tin and avidin (DBA, Milan, Italy), respectively. Sec-
tions were washed with PBS and incubated with
secondary antibody. Specific labelling was detected
with a biotin-conjugated goat anti-rabbit IgG and
avidin–biotin peroxidase complex (Vectastain ABC
kit, VECTOR). The immunostaining was developed
with peroxidase substrate kit DAB (Vector Laborator-
ies, Inc.) (brown color) and counterstaining with
hematoxylin (blue background).
To verify the binding specificity, some sections were
also incubated with only the primary antibody (no sec-
ondary) or with only the secondary antibody (no pri-
mary). In these cases no positive staining was found in
the sections, indicating that the immunoreaction was
positive in all the experiments carried out.
All sections were obtained using light microscopy
(LEICA DM 2000 combined with LEICA ICC50 HD
camera). Leica Application Suite V4.2.0 software was
used as image computer program to acquire immuno-
histochemical pictures.
Western blot analysis
All the extraction procedures were performed on ice
using ice-cold reagents. In brief, spinal cord tissues were
suspended in extraction buffer containing 0.32 M su-
crose, 10 mM Tris–HCl, pH 7.4, 1 mM EGTA, 2 mM
EDTA, 5 mM NaN3, 10 mM 2-mercaptoethanol, 50 mM
NaF, protease inhibitor tablets (Roche Applied Science,
Monza, Italy), and they were homogenized at the highest
setting for 2 min. The homogenates were chilled on ice
for 15 min and then centrifuged at 1000 g for 10 min at
4 °C, and the supernatant (cytosol + membrane extract
from spinal cord tissue) was collected to evaluate con-
tent of cytoplasmic proteins.
The pellets were suspended in the supplied
complete lysis buffer containing 1 % Triton X-100,
150 mM NaCl, 10 mM Tris–HCl, pH 7.4, 1 mM
EGTA, 1 mM EDTA protease inhibitors (Roche), and
then were centrifuged for 30 min at 15.000 g at 4 °C.
Then, supernatant containing nuclear extract was col-
lected to evaluate the content of nuclear proteins. Su-
pernatants were stored at −80 °C until use. Protein
concentration in homogenate was estimated by Bio-
Rad Protein Assay (Bio-Rad, Segrate, Italy) using BSA
as standard, and 20 μg of cytosol and nuclear extract
from each sample were analyzed.
Proteins were separated on sodium dodecyl sulfate-
polyacrylamide minigels and transferred onto PVDF
membranes (Immobilon-P Transfer membrane, Milli-
pore), blocked with PBS containing 5 % nonfat dried
milk (PM) for 45 min at room temperature, and subse-
quently probed at 4 °C overnight with specific antibodies
for TNF-α (1:500; Cell Signaling Technology), cleaved-
caspase 3 (1:500; Cell Signaling Technology), GFAP
(1:1000; Cell Signaling Technology), IL-6 (1:500;
Abcam), IL-10 (1:250; Santa Cruz Biotechnology Inc),
TGF-β (1:500; Abcam) and IFN-γ (1:250; Santa Cruz
Biotechnology Inc) in 1x PBS, 5 % (w/v) non fat dried
milk, 0.1 % Tween-20 (PMT). HRP-conjugated goat
anti-mouse IgG, HRP-conjugated goat anti-rabbit IgG or
HRP-conjugated chicken anti-rat were incubated as sec-
ondary antibody (1:2000; Santa Cruz Biotechnology Inc)
for 1 h at room temperature.
To ascertain that blots were loaded with equal
amounts of protein lysates, they were also incubated
with antibody for GAPDH HRP Conjugated (1:1000;
Cell Signaling Technology) and beta-actin (1:1000;
Santa Cruz Biotechnology, Inc). The relative expres-
sion of protein bands, was visualized using an en-
hanced chemiluminescence system (Luminata Western
HRP Substrates, Millipore) and protein bands were
acquired and quantified with ChemiDoc™ MP System
(Bio-Rad) and a computer program (ImageJ software)
respectively.
Blots are representative of three separate and reprodu-
cible experiments. The statistical analysis was carried
out on three repeated blots performed on separate
experiments.
Statistical evaluation
GraphPad Prism version 6.0 program (GraphPad Soft-
ware, La Jolla, CA) was used for statistical analysis of
the data. The results were statistically analyzed using
one-way ANOVA followed by a Bonferroni post hoc
test for multiple comparisons. A p value less than or
equal to 0.05 was considered significant. Results are
expressed as the mean ± SEM of n experiments.
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Results
Pharmacokinetic parameters of CBD after topical cream
application
The summary of the pharmacokinetic parameters is
showed in Table 1. The results of the in vivo experiment
showed that the steady-state plasma concentration (Css) of
CBD were 6.1 ± 1.9 ng/mL, which were attained at 14.9 ±
12.0 h (Tlag). Also, the maximum plasma concentration
(Cmax) was 8.3 ± 2.1 ng/mL and the temperature maximum
(Tmax) was 38.2 ± 18.9. Statistical analysis was performed
by one-way analysis of variance followed by Bonferroni
post hoc analysis. A p value less than or equal to 0.05 was
considered significant. Data represent mean ± SD.
Clinical score and body weight
Clinical disease score (Fig. 1b) as well as body weight
measurement (Fig. 1c) evaluation was assessed as param-
eters of disease. In both cases, CBD-treated EAE-
affected mice show a trend of recovery over time com-
pared to untreated EAE mice, in particular following the
disease onset and until sacrifice. As displayed, mice be-
longing to the EAE group show a grading of disease with
a clinical score as mean of 5.0 ± 0.329, while mice
treated topically with 1 % CBD-cream revealed a lower
grade of disability with a clinical score as mean of 1.5 ±
0.214. (Fig. 1b). In addition, in mice pharmacologically
treated the recovery of the clinical score matches with
an increase of body weight. Moreover, as expected, after
EAE induction, a significant body weight loss was ob-
served in EAE mice. Mice belonging to naive group have
a normal increase in body weight as well as absence of
motor deficit.
These data confirm both the disability in mice affected
by EAE and the belief that chronic inflammation and
autoimmune conditions in animals are associated with
substantial feeding alterations.
Of note during the entire treatment period were not
detected in mice treated with 1 % CBD-cream or vehicle
cream (no plus CBD) allergic reactions in mice at cuta-
neous either at systemic level. Also, in order to confirm
this, mice were subjected to every 48 h to little samples
of blood from the tail to make a blood smear glass slide
and calculate subsequent leukocyte formula, demonstrat-
ing any alteration in percentage of leukocytes.
CBD enhances responsiveness to a mechanical stimulus
Mice subjected to EAE show many clinical and patho-
logical features of human MS, like paralysis of the hind
limbs. In order to evaluate whether topical treatment
with CBD can improve limbs sensitivity to a mechanical
stimulus, we measured by needle test mechanical allody-
nia that may arise after peripheral nerve injury (Fig. 1d).
To this purpose, a stimulus was applied on the paw
plantar surface, evaluating the paw retraction response
treshold.
In EAE mice treated topically with CBD a significantly
increased response to mechanical stimulus was evident
already from the first measurements. Moreover, EAE
mice showed no response to mechanical stimulus ap-
plied to the paw plantar, while naive animals always
responded by retracting the paw (Fig. 1d).
CBD improves histopathology of EAE
Since EAE is a demyelinating disease, CBD was evaluated
for the protective effect on myelin sheath integrity by LFB
staining at 28 days after EAE induction. Compared to naive
animals and CTRL +CBD-cream (Additional files 1A and
B, EAE mice exhibited markedly reduced myelin and
axonal structures in the spinal cord (Fig. 2a). Also, treat-
ment with 1 % CBD-cream, reduced demyelination and
axonal loss in EAE mice with a high LFB positive staining
(Fig. 2b).
The May-Grunwald Giemsa staining method was also
used to evaluate inflammatory cells infiltration. The ob-
served results clearly show considerable infiltration of
lymphocytes cells in white matter of spinal cord samples
taken from EAE mice (Fig. 2c, as shownn by square
brackets) compared with naive mice and CTRL + CBD-
cream (Additional files 1C and D). Remarkably, treat-
ment with CBD-cream led to a complete resolution of
inflammatory cells infiltration (Fig. 2d).
CBD modulates production of Treg cells and CD4 and
CD8α Tcells
To assess whether CBD was able to modulate the produc-
tion of Treg cells, we evaluated expression of the transcrip-
tion factor Foxp3 by immunohistochemical analysis. Spinal
cord sections from naive mice and CTRL +CBD-cream
(Additional files 1E and F) did not show positive staining
for Foxp3, which conversely, was positive in EAE mice
(Fig. 2e). Sections obtained from 1 % CBD-cream treated
group showed negative degree for Foxp3 (Fig. 2f).
In addition, to these observations, immunohistochemi-
cal analysis carried out in spleen sections, showed a posi-
tive staining for CD4 as well as for CD8α in EAE mice
(Fig. 3a and b). Conversely, a negative staining for CD4
and CD8α was observed in EAE mice administered with
1 % CBD-cream (Fig. 3c and d) as well as in naïve mice
and CTRL + CBD-cream (Additional files 2E, F, G and H).
Table 1 Pharmacokinetic parameters of CBD after topical
treatment with 1 % CBD-cream
Pharmacokinetic parameter CBD
Cmax (ng/mL) 8.3 ± 2.1
Tmax (hours) 38.2 ± 18.9
Css (ng/mL) 6.1 ± 1.9
Tlag (hours) 15.5 ± 12.0
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Fig. 2 (See legend on next page.)
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Also, overall quantitative analysis of immunohistochemi-
cal images showed that tissue localization for CD8α was
estimated about 35.96 % of positive staining in EAE mice,
3.63 % in EAE + 1 % CBD-cream mice and 0 in naïve
group. Also, for CD4 tissue localization was estimated
about 10.69 % of positive staining in EAE mice, 2.53 % in
EAE + 1 % CBD-cream mice and 1.02 % in naïve ones.
These images are representative of at least three experi-
ments. Values shown are the mean of three different fields
observed.
Effects CBD on GFAP expression
In order to investigate whether CBD can modulate
astrocytic activation, we evaluated GFAP expression by
immunohistochemical analysis. GFAP is considered a
marker protein for astrogliosis, and a marked positive
staining for GFAP was evident in the sections from EAE
mice (Fig. 2g), compared to naive group and CTRL +
CBD-cream (Additional files 1G and H). GFAP positive
staining was significantly reduced in animals treated top-
ically with CBD (Fig. 2h). Also, the same results were
corroborated by western blot analysis on spinal cord tis-
sues (Fig. 5e).
CBD modulates p-selectin expression
No positive staining for p-selectin was observed in longi-
tudinal sections of spinal cord from naive mice and
CTRL + CBD-cream (Additional files 1A and B), whereas
Fig. 3 Immunohistochemical analysis for CD4 in spleen tissues from EAE mice (a:10x, A1 magnification:40x) and mice treated with 1 % CBD-cream (b:10x,
B1 magnification:40x). Immunohistochemical image for CD8α localization of EAE mice (c:10x, C1 magnification:40x) compared to CBD topical treated mice
(d:10x, D1 magnification:40x) in spleen tissues
(See figure on previous page.)
Fig. 2 LFB staining compared EAE group (a:10x, A1 magnification:40x) to EAE+ 1 % CBD-cream (b:10x, B1 magnification:40x). May-Grunwald Giemsa
staining for EAE mice (c:10x, C1 magnification:40x) compared to mice treated with 1 % CBD-cream (d:10x, D1 magnification:40x). Immunohistochemical
evaluation for Foxp3 in EAE (e:20x, E1 magnification:40x) and in EAE + 1 % CBD-cream mice (f:20x, F1 magnification:40x). Immunohistochemical evaluation
for GFAP in EAE (g:10x, G1 magnification:40x) and in EAE + 1 % CBD-cream mice (h:10x, H1 magnification:40x)
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Fig. 4 (See legend on next page.)
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an intense positive staining in the vascular endothelium
of EAE mice (Fig. 4a as shown by arrows) was observed.
Conversely, negative staining for p-selectin was observed
in spinal cord tissues from mice treated with 1 % CBD-
cream (Fig. 4b).
CBD regulates inflammatory pathway
In order to investigate whether treatment with CBD can
modulate the inflammatory processes triggered by EAE in-
duction through regulating secretion of pro-inflammatory
cytokines, the expression levels of IL-1β, IL-6, TNF-α,
TGF-β and INF-γ in spinal cord samples were quantified
by immunohistochemical and western blot analysis,
respectively.
A positive staining for IL-1β was observed in spinal
cord sections of EAE mice group (Fig. 4c arrowheads in-
dicate positivity for inflammatory cells, including lym-
phocytes and neutrophils) when compared to naive mice
(Additional files 1C and D), while no positive staining
for cytokine expression was obtained in mice treated
with CBD-cream (Fig. 4d). Additionally, by western blot
analysis on homogenates of spinal cord tissues, a consid-
erable increase in TNF-α release was established in EAE
mice compared to naive animals. Conversely, levels of
TNF-α were attenuated by 1 % CBD-cream administra-
tion. (Fig. 4e).
By Western blot, we found also appreciably increased
expression of IL-6 in the spinal cord tissues from EAE
Fig. 5 Western blot analysis for IL-6 was showed in a. ****p < 0.0001 vs EAE, ****p < 0.0001 vs EAE + 1 % CBD-cream. Western blot analysis for
TGF-β (b). ***p < 0.0004 vs EAE, ***p < 0.0004 vs EAE + 1 % CBD-cream. In c was displayed western blot analysis for IFN-γ. **p < 0.0011 vs EAE, ***p
< 0.0008 vs EAE + 1 % CBD-cream. Western blot analysis for IL-10 (d). *p < 0.0326, *p < 0.0415 vs EAE + 1 % CBD-cream. In e was displayed western
blot analysis for GFAP **p < 0.0016 vs EAE, ***p < 0.0009 vs EAE + 1 % CBD-cream. ND not detectable
(See figure on previous page.)
Fig. 4 Comparision of p-selectin immunohistochemical localization between EAE mice (a:10x, A1 magnification:40x) and EAE treated mice with 1 %
CBD-cream (b:10x, B1 magnification:40x). Immunohistochemical analysis for IL-1β in spinal cord tissues from EAE mice (c:10x, C1 magnification:40x) and
mice treated with 1 % CBD-cream (d:10x, D1 magnification:40x). Western blot analysis for TNF-α was showed in e. β-actin was used as internal control.
****p < 0.0001 vs EAE, ***p < 0.0004, ***p< 0.0010 vs EAE + 1 % CBD-cream
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mice On the contrary, topical treatment with 1 % CBD-
cream diminished its levels (Fig. 5a).
Western blot analysis for TGF-β revealed that this sig-
naling pathway is strongly activated following EAE-
induction while 1 % CBD-cream treatment reduces the
expression levels of this marker (Fig. 5b). Similarly, it
was found an increased expression of INF-γ in EAE
mice, decreased by 1 % CBD-cream treatment (Fig. 5c).
Also, by western blot analysis we investigated the role
of IL-10 as antinflammatory cytokine, showing a basal
level of IL-10 expression in samples obtained from EAE
mice, whereas treatment of mice with 1 % CBD-cream
significantly increased its expression. It was not observed
an expression of IL-10 in naïve animals. (Fig. 5d).
CBD modulates production of nitrotyrosine, iNOS and
PARP
CBD could also counteract the nitrosative stress result-
ing from the EAE-induction. Spinal cord sections ob-
tained from EAE untreated mice exhibited positive
staining for nitrotyrosine (Fig. 6a as shown by arrow-
heads), iNOS (Fig. 6c arrowheads shown positivity for
inflammatory cells) and PARP (Fig. 6e as shown by ar-
rowheads) .Sections obtained from mice treated with
1 % CBD-cream showed negative staining for nitrotyro-
sine (Fig. 6b), iNOS (Fig. 6d) as well as PARP staining
(Fig. 6f ).
CBD reduces Cleaved-caspase 3 expression induced by
EAE
By Western blot, we evaluated the activation of the cas-
pase pathway, particularly, cleaved-caspase 3, which
leads to programmed cell death by cleavage of cellular
substrates. Cleaved-caspase 3 levels were appreciably in-
creased in the spinal cord tissues from EAE mice. On
the contrary, topical treatment with 1 % CBD-cream
prevented EAE-induced cleaved-caspase 3 production
(Fig. 6g).
Discussion
Cannabis sativa represents a great source of bioactive
compounds whose potential for medicinal use is cur-
rently at the center of an intense research activity,
Fig. 6 Immunohistochemical image for nitrotyrosine localization of EAE mice (a:10x, A1 magnification:40x) compared to CBD topical treated mice
(b:10x, B1 magnification:40x). Immunohistochemical evaluation for iNOS in EAE (c:10x, C1 magnification:40x) and in EAE + 1 % CBD-cream mice
(d:10x, D1 magnification:40x). Immunohistochemical analysis for PARP in spinal cord tissues from EAE mice (e) and mice treated with 1 % CBD-cream
(f). Panel g shows western blot analysis for Cleaved-caspase 3. GAPDH was used as internal control. ****p < 0.0001 vs EAE, *p < 0.0244, ****p < 0.0001 vs.
EAE + CBD-cream. ND not detectable
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especially for the management of neurodegenerative dis-
orders, and MS in particular.
In this regard it is noteworthy to consider the recent
introduction of Sativex®, a cannabinoid oromucosal spray
containing a 1:1 ratio of THC and cannabidiol CBD, for
the management of symptomatic treatment of chronic
pain and spasticity in MS patients [29]. Despite this
combination has been approved and in the current state
introduced in several countries under this formulation,
over the years the point of view of the scientific commu-
nity regarding THC and CBD is changed. Although
emerging evidence regarding putative therapeutic activ-
ities of cannabinoids, to date it remains to be overcome
limits about unavoidable psychotropic effects, exhibited
by many of them [30].
Several experimental studies have shown that CBD
possesses many properties, often wrongly attributed by
collective imagination just to THC alone and wide ex-
perimental evidences demonstrated that isolating non-
psychotropic compounds by THC component provide
beneficial effects for therapeutic use, mostly for CNS
disorders [35, 36].
To date, although CBD pharmacodynamic remains still
unclear, its pharmacokinetics appears better defined. It is
known that when orally given, due to a marked first-pass
effect, CBD bioavailability ranges between values of 13
and 19 % [37], hence the oral route is not ideal for the
therapeutic delivery of CBD, but for this reason the intra-
venous administration is preferable. Even further intrana-
sal administration could be more effective as results in the
rapid attainment of the drug blood level, but it is more
suitable for acute or breakthrough pain [38].
As CBD has low aqueous solubility and undergoes
first-pass metabolism, alternative delivery routes would
be necessary to achieve successful therapeutic effects.
An easy method of CBD administration would be
through the topical route, thus maintaining a costant
therapeutic drug level and reducing increased side ef-
fects because of the decreased peak plasma levels. It has
been demonstrated, although only a few published stud-
ies, that cannabinoids are good candidates for topical de-
livery in the treatment of chronic conditions [39, 40].
For this reason, the present work was designed to de-
fine a new topical formulation of CBD, whose intrinsic
potential as a molecule with a therapeutic effect has not
yet completely understood.
Recent studies have already described beneficial effects
of intraperitoneal administration of CBD alone or in mix-
ture with other compounds in EAE mouse model with
antinflammatory and antioxidant properties [23–25]. Ac-
cording to Rahimi et al. [41] intraperitoneally treatment
with CBD in mixture with palmitoylethanolamide (PEA)
during EAE onset reduced the severity of the neurobehav-
ioral deficits of EAE. This effect of CBD and PEA was
accompanied by decreased inflammatory cytokines ex-
pression, demyelination, axonal damage and inflammatory
cytokine expression [41].
Also, in Kozela et al. study [25] it was found that sys-
temic treatment with alone CBD during disease onset
ameliorated the severity of the clinical signs of EAE.
This effect of CBD was accompanied by diminished
axonal damage and inflammation as well as microglial
activation and T-cell recruitment in the spinal cord of
EAE mice. Also, this effect seems not to be mediated via
the known cannabinoid CB1 and CB2 receptors [25].
Similarly, our achieved results have demonstrated that
topical formulation of CBD significantly modulates many
intracellular pathways associated to EAE/MS etiopathol-
ogy, by improving clinical features correlated with sever-
ity of the pathology.
One of the first hallmarks of disease in the MOG-
induced EAE model is a reduction of body weight and on-
set of symptoms such as tail tonus and hind limb paralysis.
As expected, mice belonging to EAE group showed the
highest score of disease (about 5 points in the grading
scale of disease) against 1,5 of EAE topical treated mice.
The therapeutic effect in terms of wellness following the
CBD administration as topical treatment was a reduced
body weight loss associated with an improvement in the
disease score. Therefore, 1 % CBD-cream has proven
effective into reduce the main disease parameters.
Moreover, as known, EAE is associated with a complex
series of processes triggered by neuroinflammation and
the infiltration of immune cells into the CNS, followed
by a dysfunction of neural activity and neuronal death
[42]. Here, we confirmed findings of above cited studies,
demonstrating that 1 % CBD-cream treatment acts
counteracting leukocyte infiltration and microglial acti-
vation and improving neuroinflammation status. Hysto-
pathology of spinal cord samples supported this view
showing a marked remyelination following 1 % CBD-
cream treatment. To better understand this aspect, we
believe usefull to focus the attention on the above cited
leukocyte infiltration key-event of EAE model and critical
step into the establishment of inflammatory response and
demyelinization [ 43].
In this context, adhesion molecules, as p-selectin, play
a significant role in the induction of leukocyte-
endothelial cell adhesion and extravasation of immune
cells during pathological process [44]. Therefore, accord-
ing to a supposed action on this pathway mediated by
1 % CBD-cream treatment, it was not surprising to find
a modulated p-selectin immunolocalization.
Although as known that MS is a disease mediated by
an autoimmune attack directed against components of
the myelin sheath, the mechanisms that lead to loss of
function associated with these immunologically events
remain poorly understood. The activation of T cells and
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macrophages that secrete freely diffusable factors has an
important role in the pathogenesis of MS. These factors
are the proinflammatory cytokines and reactive oxygen
and reactive nitrogen species [45, 46]. As expected we
found increased levels of proinflammatory mediators in-
cluding IL-1β, TNF-α, IL-6, IFN-γ and TGF-β in spinal
cord from EAE mice. Remarkably, 1 % CBD-cream treat-
ment significantly attenuates the expression of all these
inflammatory markers and also regulates immune toler-
ance by increasing the production of antinflammatory
cytokines, like IL-10. This confirms that CBD was able
to decrease TNF-α, IL-2 and IFN-γ release from acti-
vated splenocytes and macrophages as reported in other
studues [47–49].
Of note, this cytokine profile suggests it as an import-
ant factor in immunopathogenesis of MS, because the
main feature of MS pathophysiology is the neuroinflam-
matory reaction.
As reported in literature it’s probably that all these me-
diators are produced by Th17 cells, that play a key role
in in autoimmune neuroinflammation and EAE develop-
ment [50]. Also, it is generally considered that Th17-
mediated inflammation is characterized by neutrophil
recruitment into the CNS and neurons killing. In this
context, mainly IFN-γ seems to have a pathological role
in the development of this autoimmune disease [51].
Our results show that the MOG-induced EAE causes
significant increases in IFN-γ expression. 1 % CBD-cream
administration, significantly diminished the expression of
this cytokine.
Moreover, several studies on MS evaluated immunosup-
pressive effect of cannabinoids demonstrated that they are
able to exert their action modulating the induction of Tre-
gulatory cells (Tregs) [13], normally involved in the main-
tenance of tolerance toward self-constituents, and limiting
inflammatory responses against foreign antigens. Treg cell
recruitment plays a key defensive role in suppression of
Th1 effector cells, which are the main T cell subtype me-
diating disease pathogenesis.
To verify if treatment with CBD can modulate the pro-
duction of Treg cells, we evaluated the expression of the
transcription factor Foxp3, as an indirect marker of
Treg. In accordance with a previous study [52], we con-
firmed a clear engagement of Treg cells during EAE,
while treatment with CBD-cream is able to deplete
Foxp3 positive cells. This leads to think that the immune
system response is somehowe restrained by topic appli-
cation of 1 % CBD-cream in EAE affected mice in cor-
relation with a lower degree of autoimmune cells activity
in these animals. Also, it is possible that 1 % CBD-cream
stimulates Th0 cell to develop into a Treg phenotype.
This observation has special relevance if we consider
that CD4 T cells expression is involved in cell-mediated
immunity and in the pathogenesis of MS, with destruction
of the axonal myelin sheath in several areas of CNS and
spinal cord being mediated mainly by self-reactive CD4 T
cells. As expected, we observed that both CD4 and also
CD8α detections were apparent in untreated EAE mice,
while topical treatment reveals the capability to counteract
the release of cytotoxic T cells.
Corroborating these results, immunostaining for GFAP,
a marker of astrocytic activation, involved in many pro-
cesses of cellular function [53], was reduced in EAE mice
treated with 1 % CBD-cream compared with untreated
mice. This potentially can be correlated with the triggering
of antioxidant mechanisms that, notoriously, interfere
with GFAP upregulation occurring in astocytes.
Looking at this first report of achieved results we feel to
state that CBD, acting as an antinflammatory agent, is
capable to reduce the inflammatory signs of MS. Never-
theless, we have obtained deeper data characterizing the
therapeutic properties of the 1 % CBD-cream preparation.
For this, we have to consider that CBD has a potent
capability to attenuate oxidative and nitrosative stress in
wide neurological disease models, although the under-
lying mechanism is still unclear.
As, it is known that several cellular mediators and pro-
inflammatory cytokines can induce iNOS, enzyme
present in actively demyelinating lesions, and that ni-
trates and nitrites are increased in the CSF and serum of
patients with MS [54]. Therefore, several studies have
suggested a role for NO and its oxidizing molecules
(such as peroxynitrite) in the immunopathogenesis of
MS as contributors of the inflammatory process [55] In
accordance with these assumptions, we demonstrated
that CBD reduces the expression of iNOS and nitrotyro-
sine in tissues from EAE treated mice, suggesting that
this compound, at least in part, may be responsible for
the reduction of cytokines production, that in turn coun-
teract the rise of iNOS levels and the downstream cas-
cade of events triggered by the inflammatory process,
reducing thus oxidative stress.
The strong link between oxidative stress and apoptosis
is well known, as is the concept that down-regulation of
nitrosative stress and protection against apoptosis within
the CNS represents an effective neuroprotective therapy
for the MS treatment. In particular, PARP expression is
correlated and in turn activated by cleaved-caspase 3.
Positive staining for PARP, responsible of DNA break-
down in apoptosis, was found in EAE mice, while it was
significantly reduced by topical treatment with CBD. In
keeping with these observations, the expression of
cleaved caspase 3, a major key regulator of apoptosis,
was evaluated displaying an attenuated expression when
CBD was topically administered.
All these results overall suggest and allow us to
hypothesize that CBD has the capability to interfere with
EAE-induced neuronal apoptotic death, attenuating, or
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even preventing the activation of cellular molecular
mechanisms triggered by severe damage.
Moreover, in the current literature CBD has been
shown to be a potent analgesic in animal models of
hyperlgesia and mechanical allodynia, as possible can-
didate for the treatment of inflammatory pain and
other common symptoms related to chronic pain
[56]. These analgesic effects of CBD might be medi-
ated by its modulation of TRPV1 receptor [57]. Fur-
thermore, there are evidences that cannabinoids
induce antinociception both via supraspinal mecha-
nisms and the interaction with peripheral CB2 recep-
tors and via activation of CB1 receptors at the spinal
cord level [58]. However, CBD shows only marginal
affinity for CB1 and CB2, and the potential involve-
ment of the endocannabinoid system might be indir-
ectly mediated by its effects on the enzymes of the
endocannabinoid system.
We also confirmed that CBD has a beneficial effect
on mechanical allodynia in EAE animals. Since mice
subjected to EAE show paralysis of the hind limbs
with a consequent loss of sensitivity, we evaluated the
effects of a CBD topical treatment applied on the
hind limbs of animals in recovering a response to a
mechanical stimulus induced on the paw plantar sur-
face. Amazingly, topical CBD significantly increased
response to mechanical stimulus from the earliest
measurements, recovering the responsiveness of the
hind limbs.
We can also affirm that the protective effects of
treatment are not due to the method of drug
administration (shaving and/or spreading of the
cream). Animals treated with cream that not contain-
ing the active ingredient did not show any improve-
ment in recovering paralysis of the hind limbs. For
us, this represent a data is of pivotal importance, and
in the event that it will be clinically confirmed, this
finding could open new opportunities for the
treatment of MS.
Conclusions
Summarizing, we have shown that the topical adminis-
tration of CBD can protect against the cascade of events
(inflammation, oxidative injury and neuronal cell death)
associated to the induction of EAE. Of note, topical
CBD application was able to recover the hind limb lost
sensitivity. This observation provides a rationale for
evaluating its clinical translation that might represent a
new concept in the management of MS.
Finally, we suggest that CBD, devoid of psychoactive
activity, could be potentially, safe and effective non inva-
sive alternatives for alleviating neuroinflammation and
neurodegeneration.
Additional files
Additional file 1: Figure S1. LFB staining shows naive group (A:10x)
and CTRL-CBD cream (B:10x). May-Grunwald Giemsa staining for naive
mice (C:10x) and mice CTRL-CBD cream (D:10x). Immunohistochemical
evaluation for Foxp3 in naive group (E:10x) and in CTRL-CBD cream
(F:10x). Immunohistochemical evaluation for GFAP in naive mice (G:10x)
and in mice CTRL-CBD cream (H:10x). (TIFF 18429 kb)
Additional file 2: Figure S2. Immunohistochemical localization for
p-selectin in naive mice (A:10x) and CTRL-CBD cream (B:10x).
Immunohistochemical analysis for IL-1β in spinal cord tissues from
naive mice (C:10x) and for CTRL-CBD cream (D:10x). Immunohistochemical
analysis for CD4 in spleen tissues from naive mice (E:10x) and for CTRL-CBD
cream (F:10x). Immunohistochemical image for CD8α localization of naive
mice (G:10x) and for CTRL-CBD cream (H:10x) in spleen tissues. (TIFF 19661 kb)
Abbreviations
CBD: Cannabidiol; EAE: Autoimmune encephalomyelitis; MS: Multiple
sclerosis; MOG35–55: Myelin oligodendrocyte glycoprotein peptide; Δ
9-
THC: Δ9-tetrahydrocannabinol; CB1: Cannabinoid receptor type 1;
CB2: Cannabinoid receptor type 2; TRPV1: Transient receptor potential vanilloid
type 1; GPR55: G protein-coupled receptor 55; 5-HT1A: 5-hydroxytryptamine
receptor subtype 1A; TNF-α: Tumor necrosis factor-alpha; IL-1β: Interleukin-1beta;
iNOS: Inducible nitric oxide synthase; ROS: Reactive oxygen species; GA: Glatiramer
acetate; NDS: Nasal delivery system; CFA: Complete Freund’s adjuvant; LFB: Luxol
Fast Blue; CSS: steady-state plasma concentration; Cmax: maximum plasma
concentration; Tmax: temperature maximum; PEA: palmitoylethanolamide;
Tregs: regulatory T cells.
Competing interests
The authors declare that they have no competing interests
Authors’ contributions
SG Drafting of the manuscript and molecular biology analysis, MG
Experimental model and data analysis and interpretation, FP Extraction and
isolation of CBD and manuscript supervision, GG Provided the Cannabis
sativa L. plant, derived from greenhouse cultivation at CRA-CIN, Rovigo (Italy)
and supervised the manuscript, PB Study concept and design: PB, EM
Designed research, performed experimental procedures and produced all
histological data. All authors read and approved the final manuscript.
Author details
1IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, contrada
Casazza, 98124 Messina, Italy. 2Dipartimento di Scienze del Farmaco,
Università del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy.
3Consiglio per le Ricerca e la sperimentazione in Agricoltura – Centro di
Ricerca per le Colture Industriali (CRA-CIN), Viale G. Amendola 82, 45100
Rovigo, Italy.
Received: 25 June 2015 Accepted: 28 September 2015
References
1. Mechoulam R, Shani A, Edery H, Grunfeld Y. Chemical basis of hashish activity.
Science. 1970;169:611–2.
2. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex
mixture of natural cannabinoids. Life Sci. 2005;78:539–48.
3. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a
peripheral receptor for cannabinoids. Nature. 1993;365:61–5.
4. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al.
Identification and functional characterization of brainstem cannabinoid CB2
receptors. Science. 2005;310:329–32.
5. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol
displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor
agonists in vitro. Br J Pharmacol. 2007;150:613–23.
6. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR,
et al. International Union of Basic and Clinical Pharmacology. LXXIX.
Giacoppo et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:48 Page 15 of 17
Cannabinoid receptors and their ligands: beyond CB(1) and CB(2).
Pharmacol Rev. 2010;62:588–631.
7. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide
spectrum of action. Rev Bras Psiquiatr. 2008;30:271–80.
8. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Vanilloid TRPV1
receptor mediates the antihyperalgesic effect of the nonpsychoactive
cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J
Pharmacol. 2004;143:247–50.
9. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J
Pharmacol. 2007;152:984–6.
10. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at
5-HT1a receptors. Neurochem Res. 2005;30:1037–43.
11. Buckley NE. The peripheral cannabinoid receptor knockout mice: an update.
Br J Pharmacol. 2008;153:309–18.
12. Valverde O, Karsak M, Zimmer A. Analysis of the endocannabinoid system
by using CB1 cannabinoid receptor knockout mice. Handb Exp Pharmacol.
2005;117–45.
13. Rieder SA, Chauhan A, Singh U, Nagarkatti M, Nagarkatti P. Cannabinoid-
induced apoptosis in immune cells as a pathway to immunosuppression.
Immunobiology. 2010;215:598–605.
14. Jean-Gilles L, Gran B, Constantinescu CS. Interaction between cytokines,
cannabinoids and the nervous system. Immunobiology. 2010;215:606–10.
15. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol–recent
advances. Chem Biodivers. 2007;4:1678–92.
16. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: a
promising drug for neurodegenerative disorders? CNS Neurosci Ther.
2009;15:65–75.
17. Giacoppo S, Mandolino G, Galuppo M, Bramanti P, Mazzon E. Cannabinoids:
new promising agents in the treatment of neurological diseases. Molecules.
2014;19:18781–816.
18. Siffrin V, Brandt AU, Herz J, Zipp F. New insights into adaptive immunity in
chronic neuroinflammation. Adv Immunol. 2007;96:1–40.
19. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221–31.
20. Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J, et al.
Current treatment strategies for multiple sclerosis - efficacy versus neurological
adverse effects. Curr Pharm Des. 2012;18:209–19.
21. Malfitano AM, Proto MC, Bifulco M. Cannabinoids in the management of
spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat.
2008;4:847–53.
22. Carrillo-Salinas FJ, Navarrete C, Mecha M, Feliu A, Collado JA, Cantarero I,
et al. A cannabigerol derivative suppresses immune responses and protects
mice from experimental autoimmune encephalomyelitis. PloS one.
2014;9:e94733.
23. Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation
related to multiple sclerosis. Br J Pharmacol. 2007;152:649–54.
24. Kubajewska I, Constantinescu CS. Cannabinoids and experimental models of
multiple sclerosis. Immunobiology. 2010;215:647–57.
25. Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, et al.
Cannabidiol inhibits pathogenic T cells, decreases spinal microglial
activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br
J Pharmacol. 2011;163:1507–19.
26. Duchi S, Ovadia H, Touitou E. Nasal administration of drugs as a new non-
invasive strategy for efficient treatment of multiple sclerosis. J
Neuroimmunol. 2013;258:32–40.
27. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al.
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for
12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664–9.
28. Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, et al. Effect of
dronabinol on progression in progressive multiple sclerosis (CUPID): a
randomised, placebo-controlled trial. Lancet Neurol. 2013;12:857–65.
29. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U,
et al. Efficacy, safety and tolerability of an orally administered cannabis
extract in the treatment of spasticity in patients with multiple sclerosis: a
randomized, double-blind, placebo-controlled, crossover study. Mult Scler.
2004;10:417–24.
30. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. Cannabidiol
interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J
Pharmacol. 1974;28:172–7.
31. Taglialatela-Scafati O, Pagani A, Scala F, De Petrocellis L, Di Marzo V, Grassi G,
et al. Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton
from Hemp. Eur J Org Chem. 2010;11:2067–72.
32. Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis
seizures in NSW, Australia: cannabis potency and cannabinoid profile. PloS
one. 2013;8:e70052.
33. Paschalidis N, Iqbal AJ, Maione F, Wood EG, Perretti M, Flower RJ, et al.
Modulation of experimental autoimmune encephalomyelitis by
endogenous annexin A1. J Neuroinflammation. 2009;6:33.
34. Rodrigues DH, Vilela MC, Barcelos LS, Pinho V, Teixeira MM, Teixeira AL. Absence
of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of
experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;222:90–4.
35. England TJ, Hind WH, Rasid NA, O'Sullivan SE. Cannabinoids in
experimental stroke: a systematic review and meta-analysis. J Cereb Blood
Flow Metab. 2015;35:348–58.
36. Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel
therapeutic agents in CNS disorders. Pharmacol Ther. 2012;133:79–97.
37. Harvey DJ, Mechoulam R. Metabolites of cannabidiol identified in human
urine. Xenobiotica. 1990;20:303–20.
38. Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL. Cannabidiol
bioavailability after nasal and transdermal application: effect of permeation
enhancers. Drug Dev Ind Pharm. 2010;36:1088–97.
39. Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol-
transdermal delivery and anti-inflammatory effect in a murine model. J
Control Release. 2003;93:377–87.
40. Touitou E, Fabian B, Dany S, Almog S. Transdermal delivery of
tetrahydrocannabinol. Int J Pharm. 1988;43:9–15.
41. Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N. Interaction
between the protective effects of cannabidiol and palmitoylethanolamide
in experimental model of multiple sclerosis in C57BL/6 mice. Neuroscience.
2015;290:279–87.
42. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy
of multiple sclerosis via animal models: 70 years of merits and culprits in
experimental autoimmune encephalomyelitis research. Brain.
2006;129:1953–71.
43. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of
autoimmunity. Nat Immunol. 2007;8:913–9.
44. Golias C, Tsoutsi E, Matziridis A, Makridis P, Batistatou A, Charalabopoulos K.
Review. Leukocyte and endothelial cell adhesion molecules in inflammation
focusing on inflammatory heart disease. In vivo. 2007;21:757–69.
45. Brosnan CF, Raine CS. Mechanisms of immune injury in multiple sclerosis.
Brain Pathol. 1996;6:243–57.
46. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T.
Cannabidiol inhibits inducible nitric oxide synthase protein expression and
nitric oxide production in beta-amyloid stimulated PC12 neurons through
p38 MAP kinase and NF-kappaB involvement. Neurosci Lett. 2006;399:91–5.
47. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al.
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic
therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A.
2000;97:9561–6.
48. Jan TR, Su ST, Wu HY, Liao MH. Suppressive effects of cannabidiol on
antigen-specific antibody production and functional activity of
splenocytes in ovalbumin-sensitized BALB/c mice. Int
Immunopharmacol. 2007;7:773–80.
49. Kaplan BLF, Springs AEB, Kaminski NE. The profile of immune modulation by
cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells
(NFAT). Biochem Pharmacol. 2008;76:726–37.
50. Lovett-Racke AE, Yang Y, Racke MK. Th1 versus Th17: are T cell cytokines
relevant in multiple sclerosis? Biochim Biophys Acta. 1812;2011:246–51.
51. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S,
et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured
neurons and neurotrophin production by CNS-infiltrating T and natural killer
cells. J Neurosci. 2000;20:5283–91.
52. Zorzella-Pezavento SF, Chiuso-Minicucci F, Franca TG, Ishikawa LL, da Rosa LC,
Marques C, et al. Persistent inflammation in the CNS during chronic EAE
despite local absence of IL-17 production. Mediators Inflamm.
2013;2013:519627.
53. Eng LF, Ghirnikar RS. GFAP and astrogliosis. Brain Pathol. 1994;4:229–37.
54. Lindquist S, Hassinger S, Lindquist JA, Sailer M. The balance of pro-inflammatory
and trophic factors in multiple sclerosis patients: effects of acute relapse and
immunomodulatory treatment. Mult Scler. 2011;17:851–66.
55. Cross AH, Manning PT, Stern MK, Misko TP. Evidence for the production of
peroxynitrite in inflammatory CNS demyelination. J Neuroimmunol.
1997;80:121–30.
Giacoppo et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:48 Page 16 of 17
56. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for
neuropathic pain: from the bench to the bedside. Neurotherapeutics.
2009;6:713–37.
57. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-
psychoactive cannabis constituent cannabidiol is an orally effective
therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J
Pharmacol. 2007;556:75–83.
58. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by
endogenous cannabinoids. Nature. 1998;394:277–81.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Giacoppo et al. DARU Journal of Pharmaceutical Sciences  (2015) 23:48 Page 17 of 17
